<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="FOR AN UPDATE? Clinical trials with the neuraminidase inhibitors (NIs)" exact="oseltamivir" post="and zanamivir and and meta-analyses of oseltamivir therapy administered"/>
 <result pre="UPDATE? Clinical trials with the neuraminidase inhibitors (NIs) oseltamivir and" exact="zanamivir" post="and and meta-analyses of oseltamivir therapy administered within 36"/>
 <result pre="neuraminidase inhibitors (NIs) oseltamivir and zanamivir and and meta-analyses of" exact="oseltamivir" post="therapy administered within 36 h to 48 h of"/>
 <result pre="treatment after onset of symptoms (4). Earlier therapy with oral" exact="oseltamivir" post="administered within 12 h of symptom onset was shown"/>
 <result pre="was shown to reduce symptoms by 3.6 days (5). Inhaled" exact="zanamivir" post="shortened the duration of major influenza symptoms by 3"/>
 <result pre="placebo in individuals who were febrile at enrollment and received" exact="zanamivir" post="within 30 h (3). In low-risk outpatients, NI treatment"/>
 <result pre="H3N2 subtype and H1N1 pandemic subtype treated in hospital with" exact="oseltamivir" post="clearly demonstrate reduction in mortality, and this benefit was"/>
 <result pre="reduction in mortality, and this benefit was still observed if" exact="oseltamivir" post="was started up to 4 to 5 days after"/>
 <result pre="the predominating H3N2 virus isolates of influenza are susceptible to" exact="oseltamivir" post="and zanamivir. All isolates of H1N1 are oseltamivir- and"/>
 <result pre="Almost all isolates of influenza B are also susceptible to" exact="oseltamivir" post="and zanamivir. C. WHAT INVESTIGATIONS ARE REQUIRED TO DIAGNOSE"/>
 <result pre="onset of influenza-like symptoms. However, in severe illness requiring hospitalization," exact="oseltamivir" post="treatment has been shown to reduce mortality even if"/>
 <result pre="virus testing, treatment should be started immediately, most frequently with" exact="oseltamivir" post="orally. For adults with normal renal function, the typical"/>
 <result pre="mg every 12 h for five days. In ventilated patients," exact="oseltamivir" post="should be administered by nasogastric tube. If zanamivir is"/>
 <result pre="ventilated patients, oseltamivir should be administered by nasogastric tube. If" exact="zanamivir" post="is required in a severely ill patient, intravenous zanamivir"/>
 <result pre="If zanamivir is required in a severely ill patient, intravenous" exact="zanamivir" post="is recommended at a dose of 600 mg every"/>
 <result pre="a dose of 600 mg every 12 h. If intravenous" exact="zanamivir" post="is needed, it can be obtained by request to"/>
 <result pre="(0830-1630 weekdays), 613-941-3061 (after hours and weekends), fax 613-941-3194). Inhaled" exact="zanamivir" post="is not advised in a severely ill patient because"/>
 <result pre="through ventilator circuits is contraindicated. The recommended dose of oral" exact="oseltamivir" post="suspension for pediatric patients is shown Table 1, as"/>
 <result pre="used by adult patients who cannot swallow a capsule. If" exact="oseltamivir" post="oral suspension is not available, oseltamivir capsules may be"/>
 <result pre="swallow a capsule. If oseltamivir oral suspension is not available," exact="oseltamivir" post="capsules may be opened and mixed with sweetened liquids"/>
 <result pre="should be sent for viral PCR and susceptibility testing for" exact="oseltamivir" post="resistance. Suspected oseltamivir resistance should prompt a switch to"/>
 <result pre="for viral PCR and susceptibility testing for oseltamivir resistance. Suspected" exact="oseltamivir" post="resistance should prompt a switch to intravenous zanamivir until"/>
 <result pre="resistance. Suspected oseltamivir resistance should prompt a switch to intravenous" exact="zanamivir" post="until results of antiviral susceptibility testing are available. Repeated"/>
 <result pre="case can be reduced by early institution of post-exposure prophylactic" exact="oseltamivir" post="or zanamivir (16). Hospitalized patients and HCW, regardless of"/>
 <result pre="be reduced by early institution of post-exposure prophylactic oseltamivir or" exact="zanamivir" post="(16). Hospitalized patients and HCW, regardless of their vaccine"/>
 <result pre="contact with a patient with ILI, may be offered either" exact="oseltamivir" post="at a dose of 75 mg once daily or"/>
 <result pre="oseltamivir at a dose of 75 mg once daily or" exact="zanamivir" post="inhalation, two puffs (10 mg) once daily for seven"/>
 <result pre="receive post-exposure antiviral prophylaxis. Pre-exposure prophylaxis Pre-exposure prophylaxis with either" exact="oseltamivir" post="or zanamivir for hospitalized patients or staff is not"/>
 <result pre="antiviral prophylaxis. Pre-exposure prophylaxis Pre-exposure prophylaxis with either oseltamivir or" exact="zanamivir" post="for hospitalized patients or staff is not routinely recommended."/>
 <result pre="Michel Laverdiere: None. References REFERENCES 1.NicholsonKAokiFYOsterhausADet al.Efficacy and safety of" exact="oseltamivir" post="in treatment of acute influenza: A randomized controlled trialLancet200035518455010866439"/>
 <result pre="Trialists) Study GroupRandomised trial of efficacy and safety of inhaled" exact="zanamivir" post="in treatment of influenza A and B virus infectionsLancet19983521877819863784"/>
 <result pre="virus infectionsLancet19983521877819863784 3.HaydenFGOsterhausADMETreanorJJet al.Efficacy and safety of the neuraminidase inhibitor" exact="zanamivir" post="in the treatment of influenzaviris infectionsNew Engl J Med1997337874809302301"/>
 <result pre="and summary of regulatory commentsBMJ2014348g254524811411 5.AokiFYMacleodMDPaggiaroPet al.Early administration of oral" exact="oseltamivir" post="increases the benefits of influenza treatmentJ Antimicrob Ther2003511239 6.AokiFYAllenUDStiverHGLaverdièreMEvansGAThe"/>
 <result pre="and pathogenicity: Observation-based trialsAm J Epidemiol20071652122117088311 TABLE 1 Oseltamivir and" exact="zanamivir" post="treatment of influenza Updated from: The use of antiviral"/>
 <result pre="prescription instructions match the dosing device. 2.The above dosage provides" exact="oseltamivir" post="exposure in children similar to that achieved by the"/>
 <result pre="for adults (13–15). The American Academy of Pediatrics recommended an" exact="oseltamivir" post="treatment dose of 3.5 mg/kg orally twice daily for"/>
 <result pre="in the case of premature infants for whom treatment with" exact="oseltamivir" post="is being considered. The current weight-based dosing recommendations are"/>
 <result pre="premature infants as they might have slower clearance of oral" exact="oseltamivir" post="because of immature renal function. The following dosing is"/>
 <result pre="disease that increase the risk of bronchospasm. TABLE 2 Recommended" exact="oseltamivir" post="regimens for prevention and treatment of adult patients with"/>
</results>
